Invasive Aspergillosis Therapeutics
1. Cancidas patent expiration
Treatment: Cancidas is indicated for empirical therapy for presumed fungal infections in febrile, neutropenic patients.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514650 | MERCK | Aza cyclohexapeptide compounds |
Jan, 2015
(10 years ago) | |
| US5792746 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US6136783 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5792746 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
|
US5378804 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Sep, 2013
(12 years ago) | |
| US5378804 | MERCK | Aza cyclohexapeptide compounds |
Mar, 2013
(12 years ago) | |
| US5952300 | MERCK | Antifungal compositions |
Mar, 2017
(8 years ago) | |
|
US5514650 (Pediatric) | MERCK | Aza cyclohexapeptide compounds |
Jul, 2015
(10 years ago) | |
|
US5952300 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
|
US6136783 (Pediatric) | MERCK | Antifungal compositions |
Sep, 2017
(8 years ago) | |
Drugs and Companies using CASPOFUNGIN ACETATE ingredient
Market Authorisation Date: 26 January, 2001
Dosage: POWDER
How can I launch a generic of CANCIDAS before it's drug patent expiration?
More Information on Dosage
CANCIDAS family patents
2. Cresemba patent expiration
Treatment: NA
CRESEMBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7459561 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2020
(5 years ago) | |
| US10812238 | ASTELLAS | Configurable reference signals |
Oct, 2025
(2 months ago) | |
| US6812238 | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Oct, 2025
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(1 year, 8 months from now) | |
| US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(1 year, 8 months from now) | |
|
US6812238 (Pediatric) | ASTELLAS | N-substituted carbamoyloxyalkyl-azolium derivatives |
Apr, 2026
(3 months from now) | |
|
US10603280 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Mar, 2028
(2 years from now) | |
|
US10206879 (Pediatric) | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2020 |
| Orphan Drug Exclusivity(ODE) | Mar 06, 2022 |
| ODE*(ODE*) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-305) | Mar 06, 2022 |
| Orphan Drug Exclusivity(ODE-90) | Mar 06, 2022 |
| New Patient Population(NPP) | Dec 08, 2026 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 06, 2027 |
| Orphan Drug Exclusivity(ODE-453) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-454) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-458) | Dec 08, 2030 |
| Orphan Drug Exclusivity(ODE-459) | Dec 08, 2030 |
| Pediatric Exclusivity(PED) | Jun 08, 2031 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 08 June, 2030
Market Authorisation Date: 06 March, 2015
Dosage: POWDER; CAPSULE
More Information on Dosage
CRESEMBA family patents
3. Noxafil patent
expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(3 years ago) | |
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Dosage: SUSPENSION
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
4. Noxafil patent expiration
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
NOXAFIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(6 years ago) | |
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(5 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(5 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(7 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
| New Patient Population(NPP) | May 31, 2024 |
| New Indication(I-881) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Dosage: SOLUTION; TABLET, DELAYED RELEASE
How can I launch a generic of NOXAFIL before it's drug patent expiration?
More Information on Dosage
NOXAFIL family patents
5. Vfend patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5567817 | PF PRISM CV | Triazole antifungal agents |
May, 2016
(9 years ago) | |
| US6632803 | PF PRISM CV | Pharmaceutical formulations containing voriconazole |
Jun, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 29, 2022 |
Drugs and Companies using VORICONAZOLE ingredient
Market Authorisation Date: 24 May, 2002
Dosage: TABLET; POWDER; FOR SUSPENSION
How can I launch a generic of VFEND before it's drug patent expiration?
More Information on Dosage
VFEND family patents